ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQR · Nasdaq

ProQR Therapeutics N.V. (PRQR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for ProQR Therapeutics N.V. in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 76 days

EPS estimate

-0.12

Revenue estimate

4.6M

Past earnings

13 Aug 2026
EPS actual
-0.09 (+29.7%)
estimate -0.13
Revenue actual
10.0M (+119.7%)
estimate 4.6M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.15 (-8.6%)
estimate -0.14
Revenue actual
2.3M (-54.7%)
estimate 5.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 May 2026
EPS actual
—
estimate -0.14
Revenue actual
—
estimate 5.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Mar 2026
EPS actual
-0.09 (+10.0%)
estimate -0.10
Revenue actual
5.5M (-16.4%)
estimate 6.6M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Nov 2025
EPS actual
-0.12 (+0.8%)
estimate -0.12
Revenue actual
3.4M (-42.9%)
estimate 5.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

ProQR Therapeutics N.V. beat consensus estimates in its latest earnings report, with EPS of USD -0.0915 coming in ahead of the USD -0.1303 estimate and revenue of USD 10.02 million exceeding the USD 4.56 million forecast by 119.7%. In the prior report both EPS and revenue were below expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
Country
Netherlands
Exchange
Nasdaq
CEO
Daniel Anton de Boer
Employees
166
IPO date
18 Sep 2014
ISIN
NL0010872495
Website
proqr.com

Frequently asked questions

When does ProQR Therapeutics N.V. (PRQR) next report earnings?

ProQR Therapeutics N.V. (PRQR) is scheduled to report earnings on November 5, 2026.

What was ProQR Therapeutics N.V.'s most recent earnings date?

ProQR Therapeutics N.V. (PRQR) last reported earnings on August 13, 2026.

Where is ProQR Therapeutics N.V. stock listed?

ProQR Therapeutics N.V. (PRQR) is listed on Nasdaq.